

Attorney Docket No.: ISPH-0771
Inventors: Bennett et al.
Serial No.: 10/655,801
Filing Date: September 5, 2003
Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): An antisense compound 8 to 30 nucleobases in length which specifically hybridizes to nucleobases 14 through 177 of a 5'-untranslated region of ~~targeted to~~ a nucleic acid molecule encoding human inducible nitric oxide synthase (SEQ ID NO:3), wherein said antisense compound ~~specifically hybridizes with and~~ inhibits the expression of human inducible nitric oxide synthase.

Claim 2 (original): The antisense compound of claim 1 which is an antisense oligonucleotide.

Claim 3 (canceled).

Claim 4 (original): The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 5 (original): The antisense compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Attorney Docket No.: ISPH-0771
Inventors: Bennett et al.
Serial No.: 10/655,801
Filing Date: September 5, 2003
Page 3

Claim 6 (original): The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 7 (original): The antisense compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

Claim 8 (original): The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (original): The antisense compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10 (original): The antisense compound of claim 1 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11 (original): A pharmaceutical composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 12 (original): The pharmaceutical composition of claim 11 further comprising a colloidal dispersion system.

Attorney Docket No.: ISPH-0771
Inventors: Bennett et al.
Serial No.: 10/655,801
Filing Date: September 5, 2003
Page 4

Claim 13 (original): The pharmaceutical composition of claim 11 wherein the antisense compound is an antisense oligonucleotide.

Claim 14 (original): A method of inhibiting the expression of inducible nitric oxide synthase in cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 1 so that expression of inducible nitric oxide synthase is inhibited.

Claims 15-20 (canceled).